EVER4010001

targets FGFR4 via inhibition

Developed for: cancer
Investigated by: EverNov Medicines (Zhuhai Hengqin) Co., Ltd · Medidata Solutions

today NCT04699643 · Ph 1/2

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT04699643	Jul 2020 → Jun 2023	cancer	EverNov Medicines (Zhuhai Hengqin) Co., Ltd	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	EVER4010001	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04699643 ↗
Action	Inhibit	“FGFR4 Inhibitor EVER4010001” NCT04699643 ↗
Target	FGFR4	“FGFR4 Inhibitor EVER4010001” NCT04699643 ↗